// App-Quantinova.ai

342 : BGB-283, a slow-off inhibitor of RAF dimers, differentiates from vemurafenib in MAPK signaling inhibition

Researchers

Presenter

  • Ye Liu

Principal Investigators

  • Xi Yuan

  • Zhiyu Tang

  • Lai Wang

  • Lusong Luo

  • Min Wei

Medical Centers

  • BeiGene, Beijing, China

Locations

  • China

Companies

  • BeiGene (Beijing) Co

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Melanoma

  • Solid malignancies

Biomarkers

  • Mitogen-activated protein kinase

  • B-Raf proto-oncogene, serine/threonine kinase

  • Phospho-ERK

  • GTPase Nras

  • KRAS proto-oncogene, GTPase

Drug/Treatment

  • selumetinib

  • Vemurafenib

  • BGB-283

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved